The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Nasal Spray Influenza Vaccine Market In 2026, And How Will Its Value Evolve By 2030?
The nasal spray influenza vaccine market has experienced significant expansion recently. It is forecast to rise from $1.48 billion in 2025 to $1.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.7%. This historic growth is attributable to factors such as increased flu vaccination awareness, the reliance on traditional injection-based flu vaccines, government-led influenza immunization programs, occurrences of seasonal flu outbreaks, and the limited availability of needle-free options.
The nasal spray influenza vaccine market is projected for significant expansion over the coming years. This market is set to reach $2.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.7%. Key factors driving this growth include an increasing preference for needle-free delivery methods, the broadening of immunization programs for children and the elderly, increased spending on research and development for nasal vaccines, the creation of sophisticated attenuated vaccine formulations, and expanding global efforts to boost vaccination rates. Notable trends anticipated during this period encompass the wider acceptance of needle-free vaccination approaches, a heightened need for flu vaccines suitable for children, the increased application of quadrivalent live attenuated vaccines, more extensive seasonal flu prevention campaigns, and the innovation of both multi-dose and single-dose nasal vaccine formats.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp
Which Key Drivers Are Affecting The Nasal Spray Influenza Vaccine Market Development?
The growing incidence of influenza is projected to boost the market for nasal spray influenza vaccine. Influenza, a highly transmissible viral infection, primarily impacts the respiratory system, leading to symptoms such as fever, cough, sore throat, body aches, and fatigue. This rise in influenza prevalence is largely attributable to the influenza virus’s frequent genetic mutations, which enable it to bypass existing immunity and disseminate rapidly among populations. The nasal spray influenza vaccine offers protection against influenza by delivering a weakened form of the virus directly into the nasal passages, thereby stimulating an immune response at the typical entry point of the virus into the body. For instance, preliminary data from the Centers for Disease Control and Prevention (CDC), a US-based nation’s health protection agency, released in September 2024 concerning the 2023–2024 U.S. influenza season, indicated between 34 million and 75 million symptomatic illnesses, 15 million to 33 million medical visits, 380,000 to 900,000 hospitalizations, and 17,000 to 100,000 deaths. Notably, older adults (=65 years) constituted 51% of hospitalizations and 68% of deaths during this period. Consequently, the increasing prevalence of influenza is a key factor driving the expansion of the nasal spray influenza vaccine market.
What Segment Categories Shape The Nasal Spray Influenza Vaccine Market Segment Landscape?
The nasal spray influenza vaccine market covered in this report is segmented –
1) By Type: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine
2) By Administration Method: Single-Dose Administration, Multi-Dose Administration
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Online Stores, Other Distribution Channels
5) By End User: Healthcare Providers, Individuals, Government Health Departments, Pharmaceutical Companies
Subsegments:
1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV), Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Subunit Inactivated Vaccine, Adjuvanted Inactivated Vaccine, High-Dose Inactivated Vaccine
What Trends Are Transforming The Nasal Spray Influenza Vaccine Market?
Major companies operating in the nasal spray influenza vaccine market are prioritizing the development of innovative formulations, such as live attenuated influenza vaccines, to enhance immune response and improve patient compliance. A live attenuated influenza vaccine (LAIV) is a flu shot made from live, weakened influenza viruses that prevents influenza by stimulating the immune system to produce antibodies, offering protection without causing the disease, and providing a more comprehensive immune response through both local and systemic immunity, which strengthens the body’s ability to defend against future flu infections. For instance, in September 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, secured approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV), allowing it to be self-administered by adults aged up to 49 years or administered by caregivers to children aged 2 to 17 years, marking it as the first and only influenza vaccine approved for self- or caregiver-administration in the United States. This approval was granted based on extensive usability studies demonstrating individuals’ capacity to correctly self-administer the vaccine, with 100% of participants successfully delivering a full dose as instructed.
Who Are The Companies Operating Across The Nasal Spray Influenza Vaccine Market Value Chain?
Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, GSK plc, FluGen Inc., BioDiem Ltd, Codagenix Inc, Altimmune Inc, AstraZeneca PLC, MedImmune LLC, BCHT Biotechnology Co Ltd, Serum Institute of India Pvt Ltd, Vivaldi Biosciences, Vaccitech, Blue Water Vaccines, VaxInnate, INOVIO Pharmaceuticals, Cipla Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Bharat Biotech, Novavax Inc, BioNTech SE, Transgene SA, BiondVax Pharmaceuticals Ltd, Adimmune Corporation, Teva Pharmaceutical Industries Ltd
Get The Full Nasal Spray Influenza Vaccine Market Report:
https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report
Which Region Accounts For The Largest Portion Of The Nasal Spray Influenza Vaccine Market?
North America was the largest region in the nasal spray influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Nasal Spray Influenza Vaccine Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report
Browse Through More Reports Similar to the Global Nasal Spray Influenza Vaccine Market 2026, By The Business Research Company
Chronic Rhinosinusitis With Nasal Polyps Market Report 2026
Nasal Splints Market Report
https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report
Nasal Drug Delivery Technology Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model